FibroGen Appoints David DeLucia as Chief Financial Officer

Core Viewpoint - FibroGen, Inc. has appointed David DeLucia as Chief Financial Officer (CFO), effective December 16, 2024, following the resignation of Juan Graham on December 15, 2024 [1][2]. Group 1: Leadership Changes - David DeLucia will report to CEO Thane Wettig and will lead FibroGen's global finance organization [2]. - DeLucia has nearly 15 years of financial leadership experience in the life sciences industry, previously serving as Vice President at FibroGen [3][4]. Group 2: Company Strategy and Vision - CEO Thane Wettig expressed confidence in DeLucia's capabilities to lead the finance organization and contribute to the company's strategic goals, particularly in advancing FG-3246 and its companion diagnostic FG-3180 [3]. - DeLucia emphasized the company's transformation into a lean organization and its focus on developing novel therapies for cancer and related conditions [3]. Group 3: Company Overview - FibroGen is a biopharmaceutical company focused on developing novel therapies in cancer biology, with products like Roxadustat approved in multiple countries for treating anemia in chronic kidney disease [5]. - The company is also developing FG-3246, a first-in-class antibody-drug conjugate targeting CD46 for metastatic castration-resistant prostate cancer, along with a related PET imaging agent [5].